Business
Results for the year ended 31 December 2022
Results for the year ended 31 December 2022.
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n \n \n \n \n \n Poolbeg Pharma Plc\n \n \n \n \n \n \n \n \n \n Results for the year ended 31 December 2022\n \n \n \n \n Significant milestones reached, well capitalised and positioned for future growth\n \n \n \n \n \n \n \n \n London, UK 30 March 2023 - Poolbeg Pharma Plc (AIM: POLB, OTCQB: POLBF \"Poolbeg\" or the \"Company\")\n a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need,\n is pleased to announce its audited results for the year ended 31 December 2022.\n \n \n \n \n \n \n \n \n Financial & Corporate Highlights\n \n \n \n - Well capitalised with a cash balance of £16.2m at year end\n \n \n - Poolbeg-led consortium awarded €2.3m in non-dilutive funding to progress its Oral Vaccine Platform\n \n \n - Select experienced hires, bolstering the Company's capabilities in core areas such as business development and clinical operations\n \n \n \n \n \n \n \n \n Operational Highlights\n \n \n \n \n ·\n \n \n POLB 001\n \n - potential blockbuster p38 MAP Kinase inhibitor for the treatment of severe Influenza and other acute inflammatory conditions\n \n \n - \n Successfully completed the bacterial lipopolysaccharide (\"LPS\") human challenge trial in 2022\n \n \n - \n Positive results from the trial were published earlier this month. POLB 001 was shown to be safe and well tolerated and had a potent effect on systemic and localised inflammatory response in a dose dependent manner. This significant milestone demonstrates POLB 001's expected utility in severe influenza and supports its continued development in other acute inflammatory conditions\n \n \n - \n Poolbeg continues to evaluate POLB 001's potential in additional indications to fully unlock the potential value of the molecule and strengthen Poolbeg's position for partnering and out-licensing\n \n \n \n \n \n \n ·\n \n \n POLB 001 - Oncology\n \n \n \n - \n Strategically expanded POLB 001 in January 2023 as a potential treatment option for Cytokine Release Syndrome (CRS), a side-effect associated with CAR T cell therapy. Clinical trial enabling activities are underway with trial initiation in CAR T cell patients expected in H1 2024\n \n \n \n \n \n \n \n \n ·\n \n \n Artificial Intelligence (\"AI\") ...